Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DL69MN
|
|||
| Drug Name |
NNC-0385-0434
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Hypercholesterolaemia [ICD-11: 5C80.0; ICD-9: 272] | Phase 1 | [1] | |
| Company |
Novo Nordisk Plainsboro, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Target Info | Inhibitor | [1] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04058834) A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0385-0434 in Healthy Subjects and Patients With Hypercholesterolaemia. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.